GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guizhou Sanli Pharmaceutical Co Ltd (SHSE:603439) » Definitions » Interest Income

Guizhounli Pharmaceutical Co (SHSE:603439) Interest Income : ¥5 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Guizhounli Pharmaceutical Co Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Guizhounli Pharmaceutical Co's interest income for the three months ended in Mar. 2024 was ¥-1 Mil. Its interest income for the trailing twelve months (TTM) ended in Mar. 2024 was ¥5 Mil.

Guizhounli Pharmaceutical Co Interest Income Historical Data

The historical data trend for Guizhounli Pharmaceutical Co's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhounli Pharmaceutical Co Interest Income Chart

Guizhounli Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.73 5.54 7.94 6.51 4.97

Guizhounli Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.28 4.16 -6.76 8.85 -0.97

Guizhounli Pharmaceutical Co Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guizhounli Pharmaceutical Co (SHSE:603439) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guizhou Sanli Pharmaceutical Co Ltd (SHSE:603439) » Definitions » Interest Income
Comparable Companies
SZSE:300181 SZSE:301080 SHSE:603718 SHSE:603896 SHSE:688658 SZSE:301333 SHSE:603566 SHSE:688046 SHSE:600200 SHSE:688319 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Website
http://www.gz-sanli.com
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
Executives
Zhang Hong Yu Directors, senior managers
Wang Yi senior management
Zhang Qian Fan Directors, senior managers
Sheng Yong Jian Director

Guizhounli Pharmaceutical Co (SHSE:603439) Headlines

No Headlines